OAM
BMRN icon

Oppenheimer Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Oppenheimer Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,473
Closed -$368K – 1170
2024
Q2 		$368K Buy
4,473
+27
+0.6% +$2.25K ﹤0.01% 932
2024
Q1 		$388K Sell
4,446
-109
-2% -$9.76K 0.01% 899
2023
Q4 		$439K Sell
4,555
-319
-7% -$28.2K 0.01% 894
2023
Q3 		$431K Buy
4,874
+1,535
+46% +$137K 0.01% 885
2023
Q2 		$289K Sell
3,339
-280
-8% -$26.4K ﹤0.01% 978
2023
Q1 		$352K Sell
3,619
-2,395
-40% -$248K 0.01% 930
2022
Q4 		$622K Sell
6,014
-33
-0.5% -$3.1K 0.01% 790
2022
Q3 		$513K Buy
6,047
+1,873
+45% +$167K 0.01% 827
2022
Q2 		$346K Sell
4,174
-145
-3% -$11.5K 0.01% 947
2022
Q1 		$333K Sell
4,319
-7,053
-62% -$590K ﹤0.01% 1007
2021
Q4 		$1M Buy
11,372
+129
+1% +$10.6K 0.01% 774
2021
Q3 		$869K Sell
11,243
-6,087
-35% -$480K 0.01% 788
2021
Q2 		$1.45M Buy
17,330
+595
+4% +$47.2K 0.02% 637
2021
Q1 		$1.26M Sell
16,735
-10,574
-39% -$864K 0.02% 652
2020
Q4 		$2.4M Buy
27,309
+1,365
+5% +$108K 0.04% 426
2020
Q3 		$1.97M Buy
25,944
+1,453
+6% +$147K 0.04% 430
2020
Q2 		$3.02M Buy
24,491
+909
+4% +$90.3K 0.06% 322
2020
Q1 		$1.99M Buy
23,582
+3,868
+20% +$333K 0.05% 351
2019
Q4 		$1.67M Sell
19,714
-1,173
-6% -$88.6K 0.04% 471
2019
Q3 		$1.41M Buy
20,887
+1,850
+10% +$142K 0.03% 506
2019
Q2 		$1.63M Sell
19,037
-109
-0.6% -$9.32K 0.04% 461
2019
Q1 		$1.7M Sell
19,146
-11,171
-37% -$1.04M 0.04% 448
2018
Q4 		$2.58M Buy
30,317
+1
+0% +$95 0.06% 318
2018
Q3 		$2.94M Buy
30,316
+703
+2% +$70.2K 0.07% 321
2018
Q2 		$2.79M Buy
29,613
+3,747
+14% +$328K 0.07% 324
2018
Q1 		$2.1M Buy
25,866
+948
+4% +$81.4K 0.05% 370
2017
Q4 		$2.32M Hold
24,918
– – 0.06% 329
2017
Q3 		$2.32M Buy
24,918
+75
+0.3% +$6.63K 0.06% 331
2017
Q2 		$2.26M Buy
24,843
+1,122
+5% +$102K 0.06% 330
2017
Q1 		$2.08M Buy
+23,721
New +$2.11M 0.06% 343

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Oppenheimer Asset Management's BMRN Position: Q3 2024 in Review

Oppenheimer Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 4,473 shares — an estimated $368K sold.

Oppenheimer Asset Management first reported a position in BMRN in Q1 2017 and held it in 30 quarters. The position peaked at $3.02M in Q2 2020. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

  • Oppenheimer Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Oppenheimer Asset Management sold 4,473 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $368K.
  • Oppenheimer Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 30 quarters.
  • Oppenheimer Asset Management's BioMarin Pharmaceuticals position peaked at $3.02M in Q2 2020.
  • 553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Oppenheimer Asset Management's 13F filing for Q3 2024, filed 5 Nov 2024.